Name: Anti-Human CD20 (Obinutuzumab Biosimilar)
Brand: InnoCyto
SKU: 504301
Price: 250 USD
Availability: InStock

Shop Now Contact

Anti-Human CD20 (Obinutuzumab Biosimilar)

InnoCyto Product Image

Cat #	Size	Price
504301	1 mg	$250
504302	5 mg	$750
504303	20 mg	$1800

Bulk/Custom

Product Details

Clone	Obinutuzumab
Application	Flow cytometry, animal model study
Host Species	Mammalian cells
Reactivity	Human
Format	Liquid
Product Description	Obinutuzumab Biosimilar, CD20 Monoclonal Antibody
Isotype	Human IgG1
Regulatory Status	RUO
Clonality	Recombinant
Immunogen	Human CD20
Species specificity	Human
Purity	>95% by reducing SDS-PAGE
Grade	In vivo
Storage Conditions	4ºC
Maximal Shelf Life	12 months
RRID	AB_3739319
Target Name	CD20, MS4A-1
Antibody Type	Recombinant
Research Areas	B cells, Cancer Marker
See All Formats	Clone Obinutuzumab

Background Information

Obinutuzumab is a humanized monoclonal antibody belonging to the immunoglobulin G1 (IgG1) subclass, engineered to selectively target the CD20 antigen found on the surface of B lymphocytes. Structurally, Obinutuzumab is a glycoprotein with a molecular weight of approximately 150 kilodaltons (kDa), consisting of two identical heavy chains and two identical light chains linked by interchain disulfide bonds, forming the classic Y-shaped structure typical of antibodies. The molecule is produced in genetically modified mammalian expression systems and features controlled glycosylation designed to enhance its functional properties, particularly its effector interactions.

Obinutuzumab’s antigen-binding (Fab) regions contain variable domains derived from murine antibodies that confer specificity for a unique epitope on the extracellular loop of CD20, distinct from those recognized by earlier anti-CD20 antibodies. The complementarity-determining regions (CDRs) within the variable heavy (VH) and variable light (VL) domains mediate high-affinity binding through a combination of hydrophobic and electrostatic interactions. Once bound to CD20, Obinutuzumab stabilizes the receptor in specific conformations that promote direct signaling effects and induce target-cell death. This antibody is classified as a type II anti-CD20 molecule, meaning that it minimally triggers CD20 redistribution into lipid rafts and instead facilitates programmed cell death mechanisms such as actin reorganization and lysosomal disruption in vitro.

The Fc (fragment crystallizable) portion of Obinutuzumab is glycoengineered to lack core fucose residues on the N-linked oligosaccharides attached to the CH2 domains. This defucosylation increases its affinity for Fc gamma receptor IIIa (FcγRIIIa) on natural killer (NK) cells, significantly enhancing antibody-dependent cellular cytotoxicity (ADCC) compared with non-engineered IgG1 antibodies. The Fc region also interacts with the neonatal Fc receptor (FcRn), extending systemic half-life through recycling. Overall, Obinutuzumab exemplifies advanced antibody bioengineering—integrating optimized antigen binding, glycoform tuning, and Fc-mediated effector enhancement to study B-cell targeting and immune signaling mechanisms in molecular research.

Frequently Asked Questions

What are InnoCyto Biosimilar products?

InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.

How similar are these biosimilars to the original therapeutic antibody?

Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.

Are these antibodies suitable for in vivo studies?

Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.

What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?

A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.

What quality and purity standards do biosimilar antibodies meet?

All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.

Which therapeutic targets and mechanisms are covered in the Biosimilar line?

The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.

Search Tips